Our new website is coming soon, give it a try now and let us have your feedback. Take me to the Beta

Email Facebook Twitter

TSX Lithium explorer International Lithium Corp prepares to drill at Raleigh Lake
Exclusive: Hardman & Co Investor Forum - Severn Trent, Calculus Capital, Volta Finance, Residential

Alliance News

Midatech Pharma Gets FDA Approval For MTX110 Cancer Treatment Study

Tue, 16th Jan 2018 12:39

LONDON (Alliance News) - Midatech Pharma PLC said on Tuesday that it has received permission from the US Food & Drug Administration to conduct a study of a treatment for childhood brain cancer DIPG, which stands for diffuse intrinsic pontine glioma.

The AIM-listed oncology product developer said the FDA has approved further investigation of drug MTX110's efficacy in the treatment of DIPG, a form of brain tumour that is currently inoperable.

Midatech said research identified MTX110 as the most effective compound of 83 tested against human DIPG tumour cells. It has quickly brought the compound from initial formulation, at the end of 2015, through to the clinical trial stage in 2018, it added.

The study will be conducted at treatment centres at the University of California in San Francisco and the Memorial Sloan Kettering Cancer Center in New York, said Midatech. The study is expected to read out towards the end of 2019, and, if successful, expedited approval will be sought from internal regulators.

DIPG mainly occurs in young children, and has a median survival period of nine months. Midatech highlighted that the approval of MTX110 could be a significant step towards developing a treatment for DIPG, given that there is no treatment currently approved.

"Midatech has worked hard to rapidly develop and bring MTX110 through to this clinical trial. We have seen compelling data for MTX110 in pre-clinical models, and we are excited by the potential for this to be evidenced in patients as well. We are looking forward to potentially demonstrating the drug's efficacy in this disease, and making a difference to the children suffering from this devastating cancer for which palliative options are currently the only choice. MTX110 is one of our three priority programmes, and we look forward to reporting back on progress in due course," Midatech Chief Executive Jim Philips said.

Midatech shares were down 0.9% at 44.10 pence per share on Tuesday.

By Toby Woodall; tobywoodall@alliancenews.com

Copyright 2018 Alliance News Limited. All Rights Reserved.

Alliance News

Back to Alliance News

Share Price, Share Chat, Stock Market news at lse.co.uk
FREE Member Services
- Setup a personalised Watchlist and Virtual Portfolio.
- Gain access to LIVE real-time Regulatory News (RNS).
- View more Trades, Directors' Deals, and Broker Ratings.
Share Price, Share Chat, Stock Market news at lse.co.uk

Home  |  Contact Us  |  About Us  |  Advertise with Us  |  Sitemap  |  Terms & Conditions  |  Cookies  |  Privacy  |  Mobile Site  |  About this website design

Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.